F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  British Journal of Pharmacology

• Publication date

  2007-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.bjp.0707159PMID 17375086PMCID PMC2013947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics

  2007cited by this paper
• F15063, a potential antipsychotic with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile

  2007cited by this paper
• F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (III) Activity in models of cognition and negative symptoms

  2007cited by this paper
• P.3.d.004 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: I. Receptor affinity and efficacy in vitro and activity in neurochemical and neuroendocrine tests in rodents

  2006cited by this paper
• Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.

  2006cited by this paper
• P.3.d.009 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II. Profile in models predictive of efficacy against positive, negative symptoms and cognitive deficits of schizophrenia

  2006cited by this paper
• P.3.d.007 F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III. Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents

  2006cited by this paper
• Actions of Novel Antipsychotic Agents on Apomorphine-Induced PPI Disruption: Influence of Combined Serotonin 5-HT1A Receptor Activation and Dopamine D2 Receptor Blockade

  2006cited by this paper
• Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

  2006cited by this paper
• Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties

  2006cited by this paper
• The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.

  2005cited by this paper
• The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin

  2005cited by this paper
• Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.

  2005cited by this paper
• SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit

  2005cited by this paper
• Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

  2005influential reference
• Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action

  2005cited by this paper
• SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.

  2004cited by this paper
• SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.

  2004cited by this paper
• Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction

  2004cited by this paper
• Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile

  2004cited by this paper
• The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism

  2004cited by this paper
• The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.

  2004cited by this paper
• Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

  2004cited by this paper
• SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity

  2003cited by this paper
• DU-127090 Solvay/H Lundbeck.

  2003cited by this paper
• SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile

  2003cited by this paper
• Is there a role for 5-HT1A agonists in the treatment of depression?

  2003cited by this paper
• Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia.

  2002cited by this paper
• SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions

  2002influential reference
• Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride

  2002cited by this paper
• Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.

  2001cited by this paper
• Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

  2001cited by this paper
• The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

  2001cited by this paper
• Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

  2001cited by this paper
• 5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release

  2001cited by this paper
• New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.

  2001cited by this paper
• Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

  2000cited by this paper
• Repeated treatment with 8‐OH‐DPAT induces tolerance to its ability to produce the 5‐HT1A behavioural syndrome, but not to its ability to attenuate haloperidol‐induced catalepsy

  2000cited by this paper
• 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.

  2000cited by this paper
• The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.

  2000cited by this paper
• Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon.

  2000cited by this paper
• Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia.

  2000cited by this paper
• Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats

  2000cited by this paper
• Receptor pharmacology of neuroleptics: relation to clinical effects.

  1999cited by this paper
• The serotonin syndrome and its treatment

  1999cited by this paper
• Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

  1999cited by this paper
• Comparison of the Novel Antipsychotic Ziprasidone with Clozapine and Olanzapine: Inhibition of Dorsal Raphe Cell Firing and the Role of 5-HT1A Receptor Activation

  1999cited by this paper
• Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5‐HT2A sites for PCP‐induced locomotion in the rat

  1999cited by this paper
• F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.

  1998cited by this paper
• WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex.

  1998cited by this paper
• Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.

  1998cited by this paper
• Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms

  1998influential reference
• Reversal of Haloperidol-Induced Extrapyramidal Side Effects in Cebus Monkeys by 8-Hydroxy-2-(di-n-propylamino)tetralin and Its Enantiomers

  1998cited by this paper
• Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.

  1997cited by this paper
• Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

  1997cited by this paper
• Serotonin-dopamine interaction and its relevance to schizophrenia.

  1996cited by this paper
• Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin

  1996influential reference
• 5-HT1A receptor agonists: recent developments and controversial issues

  1995cited by this paper
• 5-HT1A receptor agonists: recent developments and controversial issues.

  1995cited by this paper
• Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

  1994cited by this paper
• Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication.

  1993cited by this paper
• Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics.

  1993cited by this paper
• Buspirone in the treatment of tardive dyskinesia.

  1993influential reference
• An open trial of buspirone added to neuroleptics in schizophrenic patients.

  1991influential reference
• Antagonism of 8-OH-DPAT-induced behaviour in rats.

  1990cited by this paper
• 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis.

  1988cited by this paper
• Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine

  1988cited by this paper
• Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics.

  1986cited by this paper
• Dopamine: a prolactin-inhibiting hormone.

  1985cited by this paper
• Manual of pharmacologic calculations with computer programs

  1982cited by this paper
• Prestimulus effects on human startle reflex in normals and schizophrenics.

  1978cited by this paper

• Discovery of NLX-266, an Orally Available and Metabolically Stable ERK1/2-Biased 5-HT1AR Agonist with Superior Antidepressant and Antiparkinsonian Activity

  2025cites this paper
• Radioligand and computational insight in structure - activity relationship of saccharin derivatives being ipsapirone and revospirone analogues.

  2021cites this paper
• Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy

  2019cites this paper
• Effects of Derivatives of 3-Hydroxypyridine and Succinic Acid on Stereotypical Behavior and Catalepsy in Mice

  2018cites this paper
• Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.

  2016cites this paper
• Polypharmacology of dopamine receptor ligands.

  2016cites this paper
• Verbal memory and 5-HT1A receptors in healthy volunteers--A PET study with [carbonyl-(11)C]WAY-100635.

  2016cites this paper
• Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.

  2015cites this paper
• MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol

  2015cites this paper
• Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.

  2015cites this paper
• Synthesis and dual D2 and 5-HT1A receptor binding affinities of 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones

  2014cites this paper
• Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.

  2014cites this paper
• Further evaluation of the tropane analogs of haloperidol.

  2014cites this paper
• Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.

  2014cites this paper
• Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.

  2014cites this paper
• The phytocannabinoid, Δ9‐tetrahydrocannabivarin, can act through 5‐HT1A receptors to produce antipsychotic effects

  2014cites this paper
• Leading compounds for the validation of animal models of psychopathology

  2013cites this paper
• Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

  2013cites this paper
• Exploring the role of 5-HT1A receptors in the regulation of prepulse inhibition in mice: implications for cross-species comparisons.

  2013cites this paper
• Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents.

  2012cites this paper
• Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

  2012cites this paper
• Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats.

  2012influential citation
• Effects of prolonged treatment with memantine in the MRL model of central nervous system lupus

  2012cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors

  2012cites this paper
• The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats

  2012cites this paper
• Serotonin–glutamate and serotonin–dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins

  2012cites this paper
• Serotonergic mechanisms as targets for existing and novel antipsychotics.

  2012cites this paper
• Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

  2011cites this paper
• Cross-species assessments of motor and exploratory behavior related to bipolar disorder.

  2010cites this paper
• Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

  2010cites this paper
• A decade of progress in the discovery and development of 'atypical' antipsychotics.

  2010cites this paper
• The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.

  2010cites this paper
• Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism.

  2010cites this paper
• The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice

  2010cites this paper
• Intrathecal antibodies and brain damage in autoimmune MRL mice.

  2010cites this paper
• Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat.

  2010cites this paper
• Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

  2009cites this paper
• Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.

  2009cites this paper
• F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.

  2009cites this paper
• F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.

  2009cites this paper
• Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms

  2009cites this paper
• Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.

  2008cites this paper
• Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics

  2008cites this paper
• Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.

  2008cites this paper
• Serotonergic approaches in the development of novel antipsychotics.

  2008cites this paper
• The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.

  2008cites this paper
• Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.

  2008cites this paper
• Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

  2008cites this paper
• Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.

  2008cites this paper
• Realistic expectations of prepulse inhibition in translational models for schizophrenia research

  2008cites this paper
• Comparison of the behavioural pharmacology of the Lister-Hooded with 2 commonly utilised albino rat strains.

  2008cites this paper
• Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice

  2008cites this paper
• Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties

  2007cites this paper
• Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.

  2007cites this paper
• F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (III) Activity in models of cognition and negative symptoms

  2007cites this paper
• Optimisation of anti‐psychotic therapeutics: a balancing act?

  2007cites this paper
• F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

  2007cites this paper
• Induction by Antipsychotics of “Win-Shift” in the Drug Discrimination Paradigm

  2007cites this paper
• Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics

  2007cites this paper
• F15063, a potential antipsychotic with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile

  2007cites this paper
• Article in Press G Model Neuroscience and Biobehavioral Reviews Cross-species Assessments of Motor and Exploratory Behavior Related to Bipolar Disorder

  year unknowncites this paper